Amendments to the Claims:

This listing will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A delayed burst release dosage form comprising a compressed core in the form of a tablet or capsule and an overcoated shell portion, said overcoated shell portion surrounding said core,

wherein said overcoated shell portion comprises a composition comprising 40 to 95 weight percent of a high molecular weight water soluble polymer having a weight average molecular weight from about 140,000 to about 1,150,000 and a cloud point from about 20 to about 90° C,

5 to 25 weight percent carrageenan, and

0.5 to 5 weight percent gellan gum,

wherein said core comprises a pharmaceutical active ingredient selected from analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, antiflatulents, antifungals, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, oral contraceptives, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof,

wherein said overcoated shell portion provides for a delayed release of the active ingredient from the dosage form such that release of the pharmaceutical active ingredient is delayed for a predetermined time after ingestion and wherein after said predetermined time said pharmaceutical active ingredient is promptly released.

2. (Previously Presented) The dosage form of claim 1, wherein the water soluble polymer is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, and mixtures thereof.

3. (Previously Presented) The dosage form of claim 2, wherein the water soluble polymer comprises hydroxypropyl methylcellulose having a viscosity from about 80 to about 120,000 mPa s in 2% aqueous solution.

4. (Previously Presented) The dosage form of claim 1, further comprising an inorganic cation.

5. (Previously Presented) The dosage form of claim 4, wherein the inorganic cation is selected from the group consisting of potassium cations, calcium cations, and mixtures thereof.

6. (Previously Presented) The dosage form of claim 1, further comprising a lubricant.

7. (Previously Presented) The dosage form of claim 6, wherein the lubricant is glyceryl monostearate.

8. (Currently Amended) The dosage form of claim 1 wherein the shell portion is in solid form and ~~is substantially free of pores having a diameter of 0.5 to 5.0 microns~~ has a pore volume in the pore diameter range of 0.5 to 5.0 microns of less than about 0.02 cc/g.

Claims 9-31 (Canceled)

32. (Currently Amended). ~~A~~ The dosage form according to claim 1, wherein said predetermined time is at least four hours, wherein less than 20% of the pharmaceutical active ingredient is released prior to said predetermined time.

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Currently Amended). ~~A~~ The dosage form according to claim 1, wherein said core and said shell are prepared by thermal setting molding or thermal cycle molding.

37. (Canceled).

38. (New) The dosage form according to claim 8, wherein the shell portion is in solid form and has a pore volume in the pore diameter range of 0.5 to 5.0 microns of less than about 0.01 cc/g.

39. (New) The dosage form according to claim 8, wherein the shell portion is in solid form and has a pore volume in the pore diameter range of 0.5 to 5.0 microns less than about 0.005 cc/g.